JP2022543391A5 - - Google Patents
Info
- Publication number
- JP2022543391A5 JP2022543391A5 JP2022506639A JP2022506639A JP2022543391A5 JP 2022543391 A5 JP2022543391 A5 JP 2022543391A5 JP 2022506639 A JP2022506639 A JP 2022506639A JP 2022506639 A JP2022506639 A JP 2022506639A JP 2022543391 A5 JP2022543391 A5 JP 2022543391A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026003598A JP2026063085A (ja) | 2019-08-05 | 2026-01-13 | トロフィネチドの組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882998P | 2019-08-05 | 2019-08-05 | |
| US62/882,998 | 2019-08-05 | ||
| PCT/US2020/044733 WO2021026066A1 (en) | 2019-08-05 | 2020-08-03 | Compositions of trofinetide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026003598A Division JP2026063085A (ja) | 2019-08-05 | 2026-01-13 | トロフィネチドの組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022543391A JP2022543391A (ja) | 2022-10-12 |
| JP2022543391A5 true JP2022543391A5 (https=) | 2023-08-15 |
| JPWO2021026066A5 JPWO2021026066A5 (https=) | 2023-08-15 |
Family
ID=74502416
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506639A Withdrawn JP2022543391A (ja) | 2019-08-05 | 2020-08-03 | トロフィネチドの組成物 |
| JP2026003598A Pending JP2026063085A (ja) | 2019-08-05 | 2026-01-13 | トロフィネチドの組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026003598A Pending JP2026063085A (ja) | 2019-08-05 | 2026-01-13 | トロフィネチドの組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11370755B2 (https=) |
| EP (1) | EP4009962A4 (https=) |
| JP (2) | JP2022543391A (https=) |
| KR (1) | KR20220059479A (https=) |
| CN (1) | CN114667136A (https=) |
| AU (1) | AU2020324396B2 (https=) |
| BR (1) | BR112022002229A2 (https=) |
| CA (1) | CA3149633A1 (https=) |
| CL (1) | CL2022000301A1 (https=) |
| CO (1) | CO2022002616A2 (https=) |
| IL (1) | IL290324A (https=) |
| JO (1) | JOP20220027A1 (https=) |
| MX (1) | MX2022001505A (https=) |
| MY (1) | MY206115A (https=) |
| SA (1) | SA522431585B1 (https=) |
| WO (1) | WO2021026066A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220059479A (ko) | 2019-08-05 | 2022-05-10 | 뉴렌 파마슈티컬즈 리미티드 | 트로피네타이드의 조성물 |
| MX2023014655A (es) * | 2021-07-12 | 2024-01-12 | Acadia Pharm Inc | Formas cristalinas de trofinetida. |
| WO2025169163A1 (en) * | 2024-02-10 | 2025-08-14 | Teadus Pharma Private Limited | Method for the synthesis of trofinetide and its analogues |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2573765B1 (fr) * | 1984-11-23 | 1988-06-10 | Solvay | Procede pour la synthese de peptides |
| US8637567B2 (en) | 2001-05-24 | 2014-01-28 | Neuren Pharmaceuticals Ltd. | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid |
| US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
| US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
| ATE435852T1 (de) | 2001-05-24 | 2009-07-15 | Neuren Pharmaceuticals Ltd | Gpe-analoga und peptidomimetika |
| US7863304B2 (en) | 2001-05-24 | 2011-01-04 | Neuren Pharmaceuticals Limited | Analogs of glycyl-prolyl-glutamate |
| EP1888618A4 (en) * | 2005-05-23 | 2009-07-15 | Neuren Pharmaceuticals Ltd | Analogs of glycyl-prolyl-glutamate |
| WO2007106555A2 (en) | 2006-03-14 | 2007-09-20 | Neuren Pharmaceuticals Limited | Oral formulations of glycyl-2-methylprolyl-glutamate |
| EP2060580A1 (en) * | 2007-11-19 | 2009-05-20 | SOLVAY (Société Anonyme) | Process for the manufacture of persilylated peptides |
| AU2012209466C1 (en) * | 2011-01-27 | 2016-06-23 | Neuren Pharmaceuticals Limited | Treatment of Autism Spectrum Disorders using Glycyl-L-2-Methylprolyl-L-Glutamic Acid |
| US20150224164A1 (en) * | 2013-11-26 | 2015-08-13 | Neuren Pharmaceuticals Limited | Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid |
| KR20220059479A (ko) | 2019-08-05 | 2022-05-10 | 뉴렌 파마슈티컬즈 리미티드 | 트로피네타이드의 조성물 |
-
2020
- 2020-08-03 KR KR1020227006982A patent/KR20220059479A/ko active Pending
- 2020-08-03 MX MX2022001505A patent/MX2022001505A/es unknown
- 2020-08-03 EP EP20850753.3A patent/EP4009962A4/en active Pending
- 2020-08-03 WO PCT/US2020/044733 patent/WO2021026066A1/en not_active Ceased
- 2020-08-03 MY MYPI2022000626A patent/MY206115A/en unknown
- 2020-08-03 CA CA3149633A patent/CA3149633A1/en active Pending
- 2020-08-03 BR BR112022002229A patent/BR112022002229A2/pt unknown
- 2020-08-03 AU AU2020324396A patent/AU2020324396B2/en active Active
- 2020-08-03 CN CN202080062340.0A patent/CN114667136A/zh active Pending
- 2020-08-03 JP JP2022506639A patent/JP2022543391A/ja not_active Withdrawn
-
2021
- 2021-06-14 US US17/347,135 patent/US11370755B2/en active Active
-
2022
- 2022-02-01 JO JOP/2022/0027A patent/JOP20220027A1/ar unknown
- 2022-02-03 SA SA522431585A patent/SA522431585B1/ar unknown
- 2022-02-03 IL IL290324A patent/IL290324A/en unknown
- 2022-02-04 CL CL2022000301A patent/CL2022000301A1/es unknown
- 2022-03-04 CO CONC2022/0002616A patent/CO2022002616A2/es unknown
- 2022-06-23 US US17/847,736 patent/US11866406B2/en active Active
-
2023
- 2023-11-21 US US18/516,604 patent/US12297172B2/en active Active
-
2026
- 2026-01-13 JP JP2026003598A patent/JP2026063085A/ja active Pending